AS
ASPI.US ASP Isotopes Inc. Common Stock
- Market cap
- USD 267M
- P/E
- -
- P/B
- 1.08x
- ROE
- -30.6%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.
Is ASPI.US undervalued?
Graham numberThe Graham number of ASP Isotopes Inc. Common Stock cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
ASP Isotopes Inc. Common Stock fundamental analysis
No fundamental analysis for ASP Isotopes Inc. Common Stock yet.
ASP Isotopes Inc. Common Stock stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About ASP Isotopes Inc. Common Stock
ASP Isotopes Inc., a development stage advanced materials company, engages in the production, distribution, marketing, and sale of isotopes in South Africa,Hong Kong, and United States. It operates in two segments, Nuclear Fuels, and Specialist Isotopes and Related Services. The Nuclear Fuels segment focuses on the research and development of technologies and methods used to produce high-assay low-enriched uranium (HALEU) and Lithium-6 for the advanced nuclear fuels target e…
Full company profileASP Isotopes Inc. Common Stock financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 2 quarters up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
ASP Isotopes Inc. Common Stock annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2019 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|
| Income Statement | |||||||
| Revenue | 22.6M | - | 0.00 | 433K | 4.14M | 23.8M | 18.6M |
| Gross Profit | 10.8M | -19.4K | -72.6K | 139K | 1.60M | 3.41M | 6.29M |
| Operating Income | -10.3M | -2.61M | -5.10M | -16.0M | -26.4M | -57.2M | -118M |
| EBITDA | 3.84M | -2.59M | -4.87M | -16.1M | -31.6M | -157M | -110M |
| Net Income | -10.3M | -2.61M | -4.95M | -16.3M | -32.3M | -175M | -80.9M |
| EPS | -0.30 | -0.08 | -0.14 | -0.49 | -0.58 | -2.11 | -0.66 |
| Balance Sheet | |||||||
| Total Assets | - | 7.14M | 12.5M | 30.2M | 94.3M | 498M | 572M |
| Total Liabilities | - | 1.14M | 2.68M | 11.4M | 43.2M | 235M | 297M |
| Shareholders' Equity | - | 6.00M | 9.82M | 16.3M | 47.9M | 204M | 265M |
| Cash & Short-term Investments | - | 2.95M | 2.39M | 7.91M | 61.9M | 333M | 255M |
| Total Debt | - | 927K | 822K | 2.14M | 37.7M | 216M | 270M |
| Cash Flow | |||||||
| Operating Cash Flow | - | -578K | -2.94M | -5.41M | -16.7M | -37.8M | -82.2M |
| Capital Expenditure | - | 2.99M | 4.47M | 2.33M | 11.4M | 9.65M | 20.5M |
| Free Cash Flow | - | -3.57M | -7.41M | -7.74M | -28.1M | -47.4M | -103M |
| Ratios | |||||||
| ROE | - | -43.5% | -50.4% | -99.9% | -67.5% | -85.8% | -30.6% |
| ROA | - | -36.5% | -39.6% | -54.0% | -34.3% | -35.2% | -14.1% |
| Net Profit Margin | -45.3% | - | - | -3,761.0% | -780.3% | -734.2% | -434.9% |
| Debt to Equity | - | 0.15x | 0.08x | 0.13x | 0.79x | 1.06x | 1.02x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
ASP Isotopes Inc. Common Stock dividends
- Dividend yield
- -
- Forward dividend
- -
- Payout ratio
- -
- Ex-dividend date
- -
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | - | - | - |
| 2024 | USD 2.78M | 0.05 | - |
| 2023 | - | - | - |
| 2022 | - | - | - |
| 2021 | - | - | - |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Who owns ASP Isotopes Inc. Common Stock
- Insiders 10.46%
- Institutions 49.13%
- Public & others 40.41%
- Shares outstanding 153M
- Free float 133M
Top funds holding ASPI.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Vanguard MStar Total Stk Mkt Idx Invest | 4.38M | 2.86% | +21.96% | Sep 2026 |
| iShares Russell 2000 ETF | 3.53M | 2.30% | 0.00% | Oct 2026 |
| Fidelity Small Cap Index | 1.33M | 0.86% | +3.94% | Aug 2026 |
| American Beacon GLG Natrl Res ETF | 1.25M | 0.82% | 0.00% | Oct 2026 |
| iShares Russell 2000 Growth ETF | 1.12M | 0.73% | -0.38% | Oct 2026 |
| Vanguard Russell 2000 ETF | 824K | 0.54% | +23.12% | Sep 2026 |
| Range Nuclear Renaissance ETF | 754K | 0.49% | 0.00% | Oct 2026 |
| Schwab US Small-Cap ETF™ | 721K | 0.47% | +0.24% | Oct 2026 |
| Jupiter Merian Glb Eq Abs Rt I USD Acc | 696K | 0.45% | 0.00% | Jun 2026 |
| Fidelity Extended Market Index | 652K | 0.43% | +15.25% | Sep 2026 |
| Pacer Data & Infrastructure Rl EsttETF | 633K | 0.41% | 0.00% | Oct 2026 |
| iShares Micro-Cap ETF | 430K | 0.28% | 0.00% | Oct 2026 |
| Anchor FR SA Equity B | 428K | 0.28% | 0.00% | Sep 2026 |
| Vanguard Materials ETF | 410K | 0.27% | +7.21% | Sep 2026 |
| Helfin Global Flexible A (USD) Acc | 405K | 0.26% | +5.84% | Sep 2026 |
| Schwab Small Cap Index | 345K | 0.22% | +20.57% | Sep 2026 |
| BMO Equal Weight Glbl BM Hdgd to CAD ETF | 337K | 0.22% | 0.00% | Oct 2026 |
| Nuveen Equity Index R6 | 276K | 0.18% | 0.00% | Aug 2026 |
| iShares Russell 2000 Small-Cap Idx Instl | 261K | 0.17% | +19.86% | Sep 2026 |
| Inspire Small/Mid Cap ETF | 243K | 0.16% | 0.00% | Oct 2026 |
Top institutions holding ASPI.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| BlackRock Inc | 9.22M | 6.01% | +10.68% | Jun 2026 |
| Encompass Capital Advisors LLC | 6.56M | 4.28% | -5.07% | Jun 2026 |
| Vanguard Capital Management, LLC | 4.98M | 3.25% | -1.53% | Jun 2026 |
| Rovida Investment Management Ltd | 4.10M | 2.67% | 0.00% | Jun 2026 |
| UBS Group AG | 3.25M | 2.12% | +14.28% | Jun 2026 |
| Geode Capital Management, LLC | 2.95M | 1.92% | +7.50% | Jun 2026 |
| Alyeska Investment Group, L.P. | 2.84M | 1.85% | +5.62% | Jun 2026 |
| State Street Corp | 2.60M | 1.69% | +11.77% | Jun 2026 |
| Exchange Traded Concepts, LLC | 2.26M | 1.47% | +3.30% | Jun 2026 |
| Awm Investment Company Inc | 1.58M | 1.03% | -25.56% | Jun 2026 |
| BNP Paribas Investment Partners SA | 1.58M | 1.03% | +77.74% | Jun 2026 |
| Philadelphia Financial Mgmt Of San Franc | 1.34M | 0.88% | +107.15% | Jun 2026 |
| Morgan Stanley - Brokerage Accounts | 1.16M | 0.76% | -26.27% | Jun 2026 |
| Vanguard Portfolio Management, LLC | 1.12M | 0.73% | +14.15% | Jun 2026 |
| Northern Trust Corp | 1.01M | 0.66% | +7.43% | Jun 2026 |
| Charles Schwab Investment Management Inc | 935K | 0.61% | +4.25% | Jun 2026 |
| Barclays PLC | 848K | 0.55% | -16.31% | Jun 2026 |
| Marshall Wace Asset Management Ltd | 836K | 0.55% | 0.00% | Jun 2026 |
| Man Group PLC | 828K | 0.54% | 0.00% | Jun 2026 |
| Vanguard Fiduciary Trust Co | 789K | 0.51% | +4.68% | Jun 2026 |
ASP Isotopes Inc. Common Stock company profile
- Company name
- ASP Isotopes Inc. Common Stock
- Ticker
- ASPI.US
- Exchange
- USA Stocks
- Listed since
- Nov 10, 2022
- Sector
- Basic Materials
- Industry
- Metals & Mining
- Employees
- 271
- Fiscal year end
- December
- Address
- 2200 Ross Avenue, Dallas, TX, United States, 75201
- Phone
- 214 432 8219
- Website
- aspisotopes.com
About ASP Isotopes Inc. Common Stock
ASP Isotopes Inc., a development stage advanced materials company, engages in the production, distribution, marketing, and sale of isotopes in South Africa,Hong Kong, and United States. It operates in two segments, Nuclear Fuels, and Specialist Isotopes and Related Services. The Nuclear Fuels segment focuses on the research and development of technologies and methods used to produce high-assay low-enriched uranium (HALEU) and Lithium-6 for the advanced nuclear fuels target end market. Its Specialist Isotopes and Related Services segment engages in the research and development of technologies and methods used to separate high-value, low-volume isotopes, such as C-14, Mo-100 and Si-28, for target end markets, including pharmaceuticals and agrochemicals, nuclear medical imaging, and semiconductors; provision of related services; and operation of PET labs. The company offers the Aerodynamic Separation Process (ASP) technology, which separates gas species and isotopes in a volatile state; and the Quantum Enrichment (QE) technology, which separates isotopes. It also produces and commercializes Molybdenum-100, Molybdenum-98, and Ytterbium-176 for the nuclear medical industry. In addition, the company develops Zinc-68, Nickel-64, and Xenon-129/136 for the nuclear medical industry; Lithium-7, Uranium-235, and Chlorine-37 for the energy industry; and Germanium-70/72/74 for semiconductor markets. The company was incorporated in 2021 and is based in Dallas, Texas.
ASP Isotopes Inc. Common Stock management
9- Mr. Paul Elliot Mann C.F.A.Executive Chairman & CEO · born 1976
- Ms. Heather KiesslingChief Financial Officer · born 1965
- Mr. Robert AinscowChief Operating Officer · born 1977
- Mr. Nicholas Michael MitchellCo-Chief Operating Officer · born 1980
- Dr. Hendrik Strydom B. Sc, M. Sc, Ph.D.Chief Technology Officer · born 1961
- Ms. Shveta Vilas DigheHead of Investor Relations
- Mr. Donald George AinscowEVP, General Counsel & Secretary · born 1981
- Mr. Stefano MaraniPresident of Electronics & Space · born 1978
- Dr. Gerdus Kemp M.D., Ph.D.Medical Director & CEO of Pet Labs